A repeatedly applied study of BBI-4000 in patients with primary hyperhidrosis

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080224187

Enrollment

Registered

2018-12-13

Start date

2019-01-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary axillary hyperhidrosis

Interventions

investigational material(s) Generic name etc : BBI-4000 INN of investigational material : sofpironium bromide Therapeutic category code : 129 Other agents affecting peripheral nervous system Dosage an

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients diagnosed as primary axillary hyperhidrosis

Exclusion criteria

Exclusion criteria: Secondary hyperhidrosis

Design outcomes

Primary

Measure	Time frame
pharmacokinetics Plasma BBI-4000 level	—

Secondary

Measure	Time frame
safety Adverse event	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026